Posted by Michael Wonder on 23 Oct 2024
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
23 October 2024 - More evidence is needed on the clinical and cost effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.
The costs of providing donanemab, including regular infusions and intensive monitoring for serious adverse effects, balanced against the relatively small benefit it provides to patients, means it cannot currently be considered good value for the taxpayer.
